AIM
ATXS

Acrospire Investment Management’s Astria Therapeutics ATXS Stock Holding History

Acrospire Investment Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-66
Closed -$6K – 118
2017
Q2 		$6K Buy
66
+55
+500% +$4.58K 0.01% 1918
2017
Q1 		$1K Buy
+11
New +$1.51K ﹤0.01% 2138
2016
Q4 		– Sell
-17
Closed -$6K – 2190
2016
Q3 		$6K Buy
+17
New +$4.48K ﹤0.01% 1790

Other funds holding ATXS

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Acrospire Investment Management's ATXS Position: Q3 2017 in Review

Acrospire Investment Management sold out of Astria Therapeutics (ATXS) in Q3 2017, closing a stake of 66 shares — an estimated $6K sold.

Acrospire Investment Management first reported a position in ATXS in Q3 2016 and held it in 3 quarters. The position peaked at $6K in Q2 2017. 24 funds tracked by Wall St. Rank hold ATXS as of Q3 2017.

  • Acrospire Investment Management reported no remaining Astria Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 66 Astria Therapeutics shares in Q3 2017, an estimated $6K.
  • Acrospire Investment Management first reported a position in Astria Therapeutics in Q3 2016 and held it in 3 quarters.
  • Acrospire Investment Management's Astria Therapeutics position peaked at $6K in Q2 2017.
  • 24 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.